Promising Combo for Triple-Negative Breast Cancer, but Only With a BRCA Mutation

Leggi l'articolo originale


The TOPACIO trial tested the PARP inhibitor niraparib plus pembrolizumab in women with triple-negative breast cancer.

Lascia un commento